DGAP-News

WILEX AG: Phase III ARISER data for the adjuvant treatment of clear cell renal cancer with RENCAREX(R) including retrospective subgroup analysis presented at ASCO - Seite 3

on 4 June 2013 at 3:00 p.m. CET in English. Please dial in ten minutes
before the conference call using the following dial-in numbers:

1. Germany: [phone]
2. UK: [phone]
3. USA: [phone]
4. USA Freephone: [phone]

You will be welcomed by an operator taking your name and company. The
presentation slides for the conference will be available for download at
www.wilex.de on 04 June 2013 at 2:30 p.m. CET.

About RENCAREX(R) and the ARISER study
The drug candidate RENCAREX(R) is based on the antibody Girentuximab, which
binds to the tumour-specific antigen CAIX - an antigen that is
overexpressed in clear cell renal cell carcinomas (ccRCC).

ARISER (Adjuvant RENCAREX(R) Immunotherapy trial to Study Efficacy in
non-metastasised Renal cell carcinoma) was an international, multicentre,
randomised Phase III trial that examined the efficacy of the antibody
RENCAREX(R) in comparison to placebo in the treatment of clear cell renal
cell cancer patients following complete or partial surgical removal of the
affected kidney in patients with no detectable metastases but at high risk
of recurrence. The study enrolled 864 patients that had had prior
nephrectomy of primary RCC no later than 12 weeks before study entry with
documented clear cell histology, an ECOG score of 0 or 1 and no evidence of
macroscopic or microscopic residual disease. Under the treatment schedule
patients received a once-weekly infusion of RENCAREX(R) or placebo (50:50)
for 24 weeks. Patients receiving RENCAREX(R) were dosed at 50 mg in the
first week followed by weekly doses of 20 mg during weeks 2-24.

RENCAREX(R) has Fast Track designation for ccRCC in the USA and Orphan Drug
designation for RCC in the USA and EU.

About WILEX
WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused
on oncology, the Company develops diagnostic and therapeutic product
candidates for the specific detection and targeted treatment of various
types of cancer. In the field of therapeutics, WILEX develops small
molecules (MESUPRON(R) two Phase IIa trials completed, WX-554 in Phase
Ib/II and WX-037 in preclinical development). In the field of diagnostics,
REDECTANE(R) is an antibody-based imaging in vivo diagnostic agent that is
currently in a Phase III programme. The Company also has a portfolio of
research use only tests and in vitro diagnostic agents that are marketed
via its US subsidiary WILEX Inc. in Cambridge, MA, under the brand Oncogene
Science. WILEX's subsidiary Heidelberg Pharma GmbH offers preclinical